Related references
Note: Only part of the references are listed.Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO-Insights From a Mechanistic PK/PD Model of Bone Turnover
Javier Martinez-Reina et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)
Effect of nitrogen-containing bisphosphonates on osteoclasts and osteoclastogenesis: an ultrastructural study
Yoshitoki Takagi et al.
MICROSCOPY (2021)
On the effect of antiresorptive drugs on the bone remodeling of the mandible after dental implantation: a mathematical model
Mehran Ashrafi et al.
SCIENTIFIC REPORTS (2021)
Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage
Javier Martinez-Reina et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Mechanobiological osteocyte feedback drives mechanostat regulation of bone in a multiscale computational model
Madge Martin et al.
BIOMECHANICS AND MODELING IN MECHANOBIOLOGY (2019)
Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization
Javier Martinez-Reina et al.
BONE (2019)
Postmenopausal osteoporosis
Richard Eastell et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men
Jung-woo Chae et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2014)
The influence of bone surface availability in bone remodelling-A mathematical model including coupled geometrical and biomechanical regulations of bone cells
Peter Pivonka et al.
ENGINEERING STRUCTURES (2013)
Advances in assessment of bone porosity, permeability and interstitial fluid flow
Luis Cardoso et al.
JOURNAL OF BIOMECHANICS (2013)
Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw
Parish P. Sedghizadeh et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2013)
Osteoporosis in the European Union: medical management, epidemiology and economic burden
E. Hernlund et al.
ARCHIVES OF OSTEOPOROSIS (2013)
Upper Gastrointestinal Tract Transit Times of Tablet and Drinkable Solution Formulations of Alendronate: A Bioequivalence and a Quantitative, Randomized Study using Video Deglutition
Claudia Gomez Acotto et al.
CALCIFIED TISSUE INTERNATIONAL (2012)
On the role of bone damage in calcium homeostasis
J. Martinez-Reina et al.
JOURNAL OF THEORETICAL BIOLOGY (2008)
Bisphosphonates: Mechanism of action and role in clinical practice
Mathew T. Drake et al.
MAYO CLINIC PROCEEDINGS (2008)
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
O. Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2006)
HPLC method validation and pharmacokinetic study of alendronate sodium in human urine with fluorescence detection
Hyun-Suk Kang et al.
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES (2006)
A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis
G Pillai et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing
CJ Hernandez et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis
S Cremers et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis
JM Halasy-Nagy et al.
BONE (2001)
Share Paper
